Skip to main content
. Author manuscript; available in PMC: 2008 Jul 8.
Published in final edited form as: Cancer Lett. 2007 Jan 23;252(1):104–114. doi: 10.1016/j.canlet.2006.12.010

Table 2.

PAH-albumin adducts and risk of HCC

PAH_Albumin Cases Controls OR(95% CI) OR*(95% CI)
No. % No. %
 Non-detectable 89 51.2 409 52.7 1.0 1.0
 Detectable 85 48.9 367 47.3 1.0(0.6-1.5) 0.9(0.5-1.4)
 Below mean 93 53.5 467 60.1 1.0 1.0
 Above mean 81 46.6 309 39.9 1.3(0.8-2.0) 1.1(0.7-1.8)
 Quantile 1 97 55.8 501 64.6 1.0 1.0
 Quantile 2 16 9.2 90 11.5 1.1(0.6-2.0) 1.0(0.5-2.0)
 Quantile 3 23 13.2 93 12.0 1.5(0.8-2.8) 1.2(0.6-2.4)
 Quantile 4 38 21.8 92 11.9 2.6(1.3-5.3)** 2.0§(1.0-4.2)
**

:p value <0.01

§

: p<0.05

: p for linear trend<0.05

*

: adjusted for HBsAg status, habitual smoking, and alcohol drinking

: Subjects with detectable adducts were quartiled and those in the lowest quartile combined with those with nondetectable adducts for Quantile 1